Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon May 16, 2011 6:46pm
177 Views
Post# 18584692

RE: RE: RE: Wait & C

RE: RE: RE: Wait & CI agree with KerBer. The amount of NR has dried up as of late, however given the company now focussed on monetizing their prior product development this was to be expected. Having said that one has to wonder if there is a NR being withheld to coincide with earnings release. Maybe management trying to goose a pop in the share price at earnings release time? Not saying it WILL happen, but saying it is a possibility.

Q2 is now half over and as far as messaging the story, management continues to be singing a happy tune. Street still wants to see evidence. I think the near term pull back in share price has a lot to do with floods occuring accross many NA regions (also HEM is a high beta stock and market is pulling back). Historically all the AG GPS players have been impacted by flooding and impact on farmer spending plans. However, it could also mean a stronger than anticipated 2H given the addition of postponed planting this year (HEM's other regional markets will be pressured to ramp up planting potentially to make up for NA issues). Either way, 2011 is shaping up to have strong potential. BUT, with the need for grain stock replenishment and potential yield challenges 2012 is shaping up to be even stronger, perhaps a blow out year. This not only applies to HEM, but also RAVN, TRMB, VT, POT, MOS and AGU.
Bullboard Posts